PROCEPT BioRobotics (NASDAQ:PRCT) Price Target Lowered to $30.00 at Leerink Partners

PROCEPT BioRobotics (NASDAQ:PRCT) had its price target cut by Leerink Partners from $55.00 to $30.00 in a research note published on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Several other analysts have also recently issued reports on PRCT. Wall Street Zen raised PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday. Truist Financial cut their price objective on PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Piper Sandler cut their price objective on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, TD Cowen dropped their target price on PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating on the stock in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.60.

PROCEPT BioRobotics Price Performance

Shares of PRCT stock opened at $23.63 on Thursday. PROCEPT BioRobotics has a one year low of $19.35 and a one year high of $68.70. The company has a market capitalization of $1.32 billion, a P/E ratio of -13.82 and a beta of 0.99. The company’s 50-day simple moving average is $30.18 and its two-hundred day simple moving average is $33.64. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The firm had revenue of $76.38 million for the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the firm earned ($0.35) earnings per share. As a group, equities analysts anticipate that PROCEPT BioRobotics will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Prosight Management LP raised its position in shares of PROCEPT BioRobotics by 1,692.4% in the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock valued at $43,415,000 after buying an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after buying an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after acquiring an additional 1,218,815 shares during the last quarter. Chicago Capital LLC increased its position in shares of PROCEPT BioRobotics by 175.7% during the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock worth $55,992,000 after purchasing an additional 999,873 shares during the last quarter. Finally, Westfield Capital Management Co. LP increased its position in shares of PROCEPT BioRobotics by 113.5% during the second quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock valued at $92,065,000 after acquiring an additional 849,792 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Solid cash runway and improving operating losses — Q4 showed an improved operating loss and the company ended the quarter with roughly $286.5M in cash and total liabilities of $142.2M, which supports near‑term execution. Quiver Quant Earnings Summary
• Positive Sentiment: FY‑2026 revenue guidance range ($390M–$410M) was raised/updated and sits near analyst consensus, giving some multi‑quarter visibility for modeling. Q4 Results & Guidance (GlobeNewswire)
• Neutral Sentiment: Company hosted an Investor Day outlining its multi‑year plan — strategic detail may help longer‑term sentiment but did not offset near‑term headline risk. Investor Day Release
• Negative Sentiment: Earnings and revenue misses — Q4 revenue of ~$76.4M (+11.9% YoY) and diluted loss of $0.53 missed consensus (revenue and EPS), and Q1 revenue guidance ($79M–$82M) came in well below street expectations — the primary catalyst for selling. Q4 Results & Guidance (GlobeNewswire)
• Negative Sentiment: New securities‑fraud investigation announced by law firm Ademi LLP, alleging possible inaccurate statements about financials/operations — this raises regulatory/legal overhang and investor risk. Ademi LLP Investigation
• Negative Sentiment: Multiple analyst price‑target cuts and a Bank of America downgrade to underperform (PT $20) plus cuts from Leerink, TD Cowen and Piper Sandler increased selling pressure; some firms remain constructive but consensus risk has risen. Analyst Coverage/Benzinga TD Cowen Comment
• Negative Sentiment: Heavy institutional selling and a spike in volume pushed the stock to a 52‑week low; hedge‑fund and mutual‑fund position reductions magnified the decline. Quiver Quant (institutional moves) Benzinga: 52‑Week Low

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.